Frontier IP Group - Portfolio news - The Vaccine Group raises £680,000
Portfolio news -
The proceeds will be used to accelerate development and expand the range of its novel animal vaccine technology. Targeted diseases currently fall into two broad areas: zoonotic diseases, such as Ebola, bird flus and SARs, that jump from animals to animals, including humans; and diseases, such as African swine fever and bovine tuberculosis, which impact economically important livestock. The division between the two varies around the world: bovine tuberculosis is a direct human health threat in many lower and middle countries ("LMICs").
The fundraising values the
TVG's vaccines are based on benign forms of herpesviruses, a group of viruses that are found in all animals, including humans. They are created by inserting a non-infectious region of DNA from the pathogen being targeted into the herpesvirus. This vaccine then stimulates an immune response against the disease when delivered into the animal.
· Ebola and Lassa fever, funded by the
· Streptococcus suis, an emerging zoonotic disease in pigs that can be fatal to humans, funded by the
· Bovine mastitis, funded by the global bacterial vaccine network Bactivac.
The Company is also developing vaccines to combat:
· African Swine Fever Virus, a disease currently having a devastating impact on the swine herd in many parts of the world, particularly
· Bovine tuberculosis, seen as a major animal health threat in the
TVG Founder and Chief Scientific Officer, Associate Professor Dr
| || |
T: 020 7332 2338
M: 07464 546 025
| || |
T: 0203 328 5656
| || |
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
With a mission to Advance Knowledge and Transform Lives,
It has a strong track record for teaching and learning excellence and has one of the highest numbers of National Teaching Fellows of any
*Research Fortnight Research Power
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
Quick facts: Frontier IP Group PLC
Market Cap: £31.93 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE